ZHANG Chao, SONG Cun-Xian, SUN Hong-Fan, and MA Gui-Lei
(The Tianjin Key Laboratory of Biomaterials, Institute of Biomedical Engineering, Peking Union Medical College, Chinese Academy of Medical Sciences, Tianjin 300192, China) 在知网中查找 在百度中查找 在本站中查找
As with drug-eluting stents (DES), biomacromolecule-eluting stents can deliver biologically active agents such as nucleic acid, antibody, enzyme and cell factor. Biological active agents can selectively act at specific target location through molecular mechanism of coronary artery restenosis. This seems to be a promising treatment strategy for preventing in-stent restenosis (ISR) while simultaneously reducing the risk of stent thrombosis. This article reviews recent developments in biomacromolecule-eluting stents.